Last Updated on December 31, 2023 by The Health Master
Cough syrups testing
In a startling revelation, two different NABL government laboratories have recently reported receiving identical cough syrup samples with the same batch number, all manufactured by a single exporter for the purpose of international trade.
This discovery has triggered serious concerns about the integrity and quality control measures in the pharmaceutical industry.
The Drugs Controller General India (DCGI), Central Drugs Standard Control Organization (CDSCO) have taken immediate action to address the issue and have issued a directive to all drug manufacturers and exporters.
Sending identical batches to multiple laboratories for testing is considered highly objectionable and a clear violation of industry norms.
Immediate Directive to Address the Issue
To ensure transparency and maintain high-quality standards in the pharmaceutical sector, the DCGI issued a directive on 28-07-2023 with immediate effect.
The key points of the directive are as follows:
Prohibition on Multiple Submissions:
All drug manufacturers and exporters have been strictly instructed to refrain from submitting the same batch number of cough syrup to more than one laboratory for testing purposes.
This measure aims to prevent any potential discrepancies or inconsistencies that may arise from multiple testing procedures.
Consequences of Non-Compliance:
Non-compliance with this directive will have serious repercussions.
If any further instances of identical batch submissions to multiple laboratories are reported, the samples from the concerned manufacturer/exporter will not be accepted for testing by any NABL accredited Government laboratory.
Additionally, legal action may be taken against the non-compliant parties, and their export privileges may be affected.
Commitment to Upholding Quality Assurance
In a joint statement, the DCGI, CDSCO emphasized their dedication to maintaining the highest standards of drug testing and quality assurance within the country.
The pharmaceutical industry plays a crucial role in ensuring the health and well-being of millions, both domestically and globally, and preserving the reputation of Indian medicines is of utmost importance.
Call for Compliance
This directive extends to all laboratories under the CDSCO and state-level laboratories involved in testing cough syrup samples for export purposes.
Strict compliance with the directive is expected from all parties involved to avoid any further complications.
The authorities believe that adhering to these regulations will enhance transparency, accountability, and the credibility of India’s pharmaceutical exports.
It is also crucial for ensuring the safety and efficacy of medicines for consumers worldwide.
Conclusion
The cough syrup scandal has raised concerns within the Indian pharmaceutical industry, prompting swift action from the DCGI, CDSCO.
The directive prohibiting the submission of identical cough syrup batches to multiple laboratories aims to strengthen quality assurance measures and maintain the country’s reputation as a reliable exporter of high-quality medicines.
Pharmaceutical manufacturers and exporters are urged to comply with the directive to ensure transparency and uphold the industry’s integrity.
The health and safety of patients worldwide depend on adherence to stringent quality standards, and the authorities are committed to maintaining these standards for the greater good of public health.
For any inquiries or clarifications regarding this directive, concerned parties are advised to contact the office of Drugs Controller General India (DCGI), Central Drugs Standard Control Organization (CDSCO).
Procedure to obtain License to Manufacture drugs for testing and analysis purposes
Procedure to obtain license for Commercial Testing Laboratories
Latest Notifications: Testing Laboratories
Commercial Testing Laboratories
Commercial Testing Laboratories: Procedure
Updated list of Medical Device Testing Laboratories (MDTLs)
List of Laboratory Instruments for Pharma & Cosmetics Industry
Calibration of Laboratory Instruments
NABL: List of NABL Accredited Testing Laboratories
NABL 164 released : Guidelines for Inter-laboratory comparison
NABL releases NABL 136: specific criteria for X-Ray equipment
NABL 126: Specific criteria for calibration of Medical Devices
NIPER: A Comprehensive Guide to NIPER Institutes in India
USFDA gives marketing approval for this Birth Control Pill
3D printed Medical Device developed for rapid diagnosis of UTI
Pharmacists can play a vital role in Enhancing Healthcare in India
Physical and Chemical parameters of Excipient affect its functionality and Drug Quality: Experts
Illegal Drugs worth more than Rs. 50 Lakh seized from warehouses in Agra
Drug recall: Sun Pharma, Alembic recall these drugs due to this reason
Latest on Indian Pharmacopoeia Commission (IPC)
Lok Sabha passes The Jan Vishwas Bill to Amend Drugs and Cosmetics Act
NPPA fixed ceiling prices of 915 scheduled formulations till mid July
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
